TrialClinical and experimental immunology2017

Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.

M Borte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.